
    
      The study is a randomized, double blinded, placebo-controlled, multi-center crossover
      clinical trial.

      Eligible subjects will be randomized in a 1:1 allocation ratio to one of two treatment
      schedules: first methyldopa then placebo vs. first placebo then methyldopa.

      The study objective is to assess the safety, efficacy, and mode of action of methyldopa to
      reduce DQ8 antigen presentation in individuals at Stage 1 and 2 of type 1 diabetes (T1D).
    
  